Japanese drug regulators have awarded orphan drug status to Eisai’s anticancer drug lenvatinib for the treatment of thyroid cancer Lenvatinib is an investigational anti-angiogenic agent that, according to the firm, has a unique inhibitory profile against the receptor tyrosine kinase … Continue reading
August 3, 2014
by PharmaReviews
0 comments
